We are live on
!
Find out more
Creative Planning Portfolio holdings
AUM
$171B
1-Year Est. Return
24.68%
This Fund
S&P 500
This Quarter
Est. Return
+14.14%
1 Year Est. Return
+24.68%
3 Year Est. Return
+62.17%
5 Year Est. Return
+55.89%
10 Year Est. Return
+171.9%
AUM
$171B
AUM Growth
+$23.7B
(+16%)
Cap. Flow
+$6.93B
Cap. Flow
% of AUM
4.05%
Top 10 Holdings %
Top 10 Hldgs %
41.66%
Holding
4,427
New
337
Increased
2,605
Reduced
1,239
Closed
133
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total Bond Market
BND
|
+$682M |
| 2 |
State Street SPDR Portfolio Developed World ex-US ETF
SPDW
|
+$526M |
| 3 |
Vanguard Short-Term Bond ETF
BSV
|
+$504M |
| 4 |
iShares Core S&P 500 ETF
IVV
|
+$431M |
| 5 |
State Street SPDR Portfolio S&P 400 Mid Cap ETF
SPMD
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$239M |
| 2 |
Vanguard Morningstar Large-Cap ETF
VV
|
+$74.4M |
| 3 |
Vanguard Morningstar Mid-Cap ETF
VO
|
+$41.1M |
| 4 |
Honeywell
HON
|
+$39.3M |
| 5 |
iShares Core US Aggregate Bond ETF
AGG
|
+$38.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 73.8% |
| 2 | Technology | 9.57% |
| 3 | Financials | 3.79% |
| 4 | Industrials | 2.49% |
| 5 | Healthcare | 2.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4176
Marker Therapeutics
MRKR
$19.7M
| $25.4K | ﹤0.01% |
17,312
| – | – |
|
4177
Outdoor Holding Co
POWW
$252M
| $24.9K | ﹤0.01% |
+10,915
| New | +$22.5K |
|
|
ATYR
4178
aTyr Pharma
ATYR
$48.8M
| $24.8K | ﹤0.01% |
41,593
+31,085
| +296% | +$20.3K |
|
4179
CALL
Iris Energy
IREN
$17.6B
| $24.1K | ﹤0.01% |
+1,500
| New | +$78K |
|
4180
CALL
SPDR Gold Trust
GLD
$150B
| $23.6K | ﹤0.01% |
+400
| New | +$166K |
|
4181
CALL
Meta Platforms (Facebook)
META
$1.57T
| $23.2K | ﹤0.01% |
+1,200
| New | +$734K |
|
|
LX
4182
LexinFintech Holdings
LX
$145M
| $23.1K | ﹤0.01% |
11,726
-6,842
| -37% | -$14.6K |
|
4183
CALL
Vail Resorts
MTN
$4.81B
| $22.7K | ﹤0.01% |
+2,000
| New | +$260K |
|
4184
Lucid Diagnostics
LUCD
$179M
| $22.5K | ﹤0.01% |
21,068
+6,648
| +46% | +$7.17K |
|
|
ABTC
4185
American Bitcoin Corp
ABTC
$582M
| $22.1K | ﹤0.01% |
2,159
-67
| -3% | -$1.02K |
|
4186
CALL
Baidu
BIDU
$33.7B
| $22K | ﹤0.01% |
+2,000
| New | +$248K |
|
4187
Westwater Resources
WWR
$71.8M
| $21K | ﹤0.01% |
41,676
+24,261
| +139% | +$14.4K |
|
4188
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$814B
| $20.6K | ﹤0.01% |
+200
| New | +$145K |
|
|
INFQ
4189
CALL
Infleqtion Inc
INFQ
$2.9B
| $20.5K | ﹤0.01% |
10,000
-10,000
| -50% | -$138K |
|
4190
NET Power
NPWR
$171M
| $20.4K | ﹤0.01% |
+12,217
| New | +$22.1K |
|
4191
PUT
State Street Real Estate Select Sector SPDR ETF
XLRE
$8.26B
| $19.6K | ﹤0.01% |
+7,000
| New | +$308K |
|
4192
DocGo
DCGO
$39.8M
| $19.3K | ﹤0.01% |
37,447
+26,471
| +241% | +$15.8K |
|
4193
Coherus Oncology
CHRS
$219M
| $19.2K | ﹤0.01% |
13,729
-1,015
| -7% | -$1.66K |
|
4194
Aemetis
AMTX
$132M
| $19.1K | ﹤0.01% |
11,650
| – | – |
|
4195
Myomo
MYO
$57M
| $18.7K | ﹤0.01% |
+18,010
| New | +$17.6K |
|
|
CRDL
4196
Cardiol Therapeutics
CRDL
$257M
| $18.7K | ﹤0.01% |
+17,609
| New | +$22.3K |
|
4197
INmune Bio
INMB
$67.7M
| $18.5K | ﹤0.01% |
+11,325
| New | +$15.7K |
|
4198
CALL
United States Oil Fund
USO
$1.61B
| $18K | ﹤0.01% |
+2,000
| New | +$262K |
|
4199
Lineage Cell Therapeutics
LCTX
$273M
| $17.8K | ﹤0.01% |
13,600
-85
| -0.6% | -$117 |
|
4200
CALL
Palantir
PLTR
$419B
| $17.7K | ﹤0.01% |
+700
| New | +$95.5K |
|
Similar funds
Creative Planning's Q2 2026 Portfolio in Review
As of Q2 2026, Creative Planning held 4,427 positions worth $171B, up 16% from $147B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Creative Planning deployed $6.93B of net new capital in Q2 2026, opening 337 new positions and adding to 2,605 existing holdings. Its largest new stake was Honeywell Aerospace: 169,880 shares worth $37.6M.
By sector, the portfolio is most concentrated in Miscellaneous at 74% of assets, down from 76% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Vanguard FTSE Developed Markets ETF, an estimated $239M trimmed.
- Creative Planning's largest Q2 2026 buy was Honeywell Aerospace: 169,880 shares worth $37.6M.
- Creative Planning added most to Vanguard Total Bond Market in Q2 2026, an estimated $682M increase.
- Creative Planning's biggest Q2 2026 reduction was Vanguard FTSE Developed Markets ETF, cutting an estimated $239M.
- Creative Planning fully exited Hologic in Q2 2026, selling an estimated $8.29M.
- Creative Planning's ten largest holdings make up 42% of its $171B portfolio in Q2 2026.
- Creative Planning opened 337 new positions and closed 133 in Q2 2026.
- Creative Planning's portfolio value rose 16% quarter-over-quarter to $171B.
Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.